organization · Reporting owner
Sigma Emerging Markets Ltd.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Rein Therapeutics, Inc.
Report date July 05, 2017 · Filed July 06, 2017
Section 16 reporting ended · disclosed 2017-07-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 423,086 |
Ending reported balance
After 2017-07-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-07-05 · Conversion · Acquired 233,086 · Balance 233,086 F1: The Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Row 2 · 2017-07-05 · Purchase · Acquired 190,000 · Balance 423,086 |
| Series F Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-07-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-07-05 · Conversion · Disposed 2,316,176 · Balance 0 F1: The Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 05, 2017 Filed Jul 6, 2017 22:25 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionSeries F Preferred Stock · Derivative | 2,316,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018013 · doc4.xml · derivative · entry 3 Sigma Emerging Markets Ltd. · CIK 0001709926 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 233,086 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:25 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | PurchaseCommon Stock | 190,000 | $15.00 | $2,850,000.00 |
DisclosureSEC source: 0000899243-17-018013 · doc4.xml · nonDerivative · entry 2 Sigma Emerging Markets Ltd. · CIK 0001709926 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,086 Read SEC document |
| July 05, 2017 Filed Jul 6, 2017 22:25 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | ConversionCommon Stock | 233,086 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-018013 · doc4.xml · nonDerivative · entry 1 Sigma Emerging Markets Ltd. · CIK 0001709926 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.